Vol. 6 (07) pp. 1108-1113 DOI: 10.21474/IJAR01/7464

ANTIMICROBIAL SUSCEPTIBILITY OF RAPID GROWING MYCOBACTERIA INFECTED PATIENTS WITH NTM AT TERTIARY CARE CENTER.

, , , , and
  • Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Luckow-226014.
  • Sri Satya Sai University of Technology and Medical Sciences, Bhopal, India.
26 Downloads 113 Views
Crossref

Download Full Paper (PDF)

Abstract

Rapidly growing mycobacteria (RGM) are ubiquitous organisms found in the environment and are the main cause of pulmonary NTM disease. Some species of RGM are recognized as human pathogens. Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium chelonae are most common species in RGM. It is important to correctly distinguish RGM from other species of mycobacteria for the proper treatment of disease. The aim of this study was to perform the antibiotic susceptibility of RGM isolates using standard microbroth dilution test. The study was conducted in the department of microbiology at a tertiary care hospital. This study included 125 isolates of RGM obtained from clinical specimens of suspected cases of pulmonary tuberculosis. 125 isolates of RGM were speciated by Line probe assay and Antimicrobial susceptibility testing was performed as per the guidelines provided by CLSI using Sensititre® RAPMYCO panel test (TREK Diagnostic Systems Magellan Biosciences, West Sussex, and UK). Of the 125 RGM isolates from pulmonary specimens, the majority of RGM were M. abscessus consisting of 65 (52%) strains, followed by 43 (34.4%) strains of M. fortuitum and 17 (13.6%) of M. chelonae. Amikacin was active against nearly all RGM isolates. In patients with M. abscessus, the majority of isolates were susceptible to tigecycline and amikacin followed by linezolid and then clarithromycin. For M.fortuitum the majority of strains were sensitive to amikacin, tigecycline and TMP-SMZ followed by clarithromycin, moxifloxacin, doxycycline and imipenem. M.chelonae was found to be more sensitive for amikacin, clarithromycin, tigecycline, moxifloxacin followed by doxycycline, imipenem and linezolid. Public Health Problems in RGM pulmonary diseases are going to increase. The treatment of pulmonary infections due to RGM is clearly difficult. Due to the lack of facilities and expertise, many laboratories these types of infections are undiagnosed. Our study demonstrates the importance of accurate and correct identification of isolates to the species level and antibiotic susceptibility of RGM species for proper treatment and management of patients is important. Key words Nontuberculous mycobacteria, Rapid growing mycobacteria, Sensititre broth dilution

Article Analytics

References

  1. Alcaide, F., M. Pe?a, et al. (2017). "Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994?2015." European Journal of Clinical Microbiology & Infectious Diseases 36(8): 1425-1432.
  2. Bicmen, C., M. Coskun, et al. (2010). "Nontuberculous mycobacteria isolated from pulmonary specimens between 2004 and 2009: causative agent or not?" New Microbiologica 33(4): 399-403.
  3. Broda, A., H. Jebbari, et al. (2013). "Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom." Journal of clinical microbiology 51(1): 217-223.
  4. Brown-Elliott, B. A., K. A. Nash, et al. (2012). "Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria." Clinical microbiology reviews 25(3): 545-582.
  5. Brown-Elliott, B. A. and R. J. Wallace (2002). "Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria." Clinical microbiology reviews 15(4): 716-746.
  6. Brown-Elliott, B. A., R. J. Wallace, et al. (2002). "Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria." Antimicrobial agents and chemotherapy 46(10): 3283-3285.
  7. Colombo, R. E. and K. N. Olivier (2008). Diagnosis and treatment of infections caused by rapidly growing mycobacteria. Seminars in respiratory and critical care medicine, Published Thieme Medical Publishers.
  8. Fern?ndez-Roblas, R., N. Martin-de-Hijas, et al. (2008). "In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria." Antimicrobial agents and chemotherapy 52(11): 4184-4186.
  9. Gayathri, R., K. L. Therese, et al. (2010). "Antibiotic susceptibility pattern of rapidly growing mycobacteria." Journal of postgraduate medicine 56(2): 76.
  10. Gray, T. J., F. Kong, et al. (2014). "Improved Identification of Rapidly Growing Mycobacteria by a 16S?23S Internal Transcribed Spacer Region PCR and Capillary Gel Electrophoresis." PLoS ONE 9(7): e102290.
  11. Griffith, D. E., T. Aksamit, et al. (2007). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases." American journal of respiratory and critical care medicine 175(4): 367-416.
  12. Heidarieh, P., M. Mirsaeidi, et al. (2016). "In vitro antimicrobial susceptibility of nontuberculous mycobacteria in iran." Microbial Drug Resistance 22(2): 172-178.
  13. Huang, C.-W., J.-H. Chen, et al. (2013). "Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan." International journal of antimicrobial agents 41(3): 218-223.
  14. Huang, T.-S., S. S.-J. Lee, et al. (2008). "Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002." Journal of the Formosan Medical Association 107(4): 281-287.
  15. Jarand, J., A. Levin, et al. (2011). "Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease." Clinical Infectious Diseases 52(5): 565-571.
  16. Lee, S. M., J. Jeong, et al. (2007). "Evaluation of the broth microdilution method using 2, 3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing." Journal of Korean medical science 22(5): 784-790.
  17. Lin, C., C. Russell, et al. (2018). "Increasing Prevalence of Nontuberculous Mycobacteria in Respiratory Specimens from US-Affiliated Pacific Island Jurisdictions." Emerging infectious diseases 24(3): 485.
  18. Marras, T. K. and C. L. Daley (2002). "Epidemiology of human pulmonary infection with mycobacteria nontuberculous." Clinics in chest medicine 23(3): 553-567.
  19. Nash, K. A., Y. Zhang, et al. (2005). "Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum." Journal of Antimicrobial Chemotherapy 55(2): 170-177.
  20. Park, S., S. Kim, et al. (2008). "In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea." Journal of Korean medical science 23(1): 49-52.
  21. Piersimoni, C. and C. Scarparo (2009). "Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons." Emerging infectious diseases 15(9): 1351.
  22. Prevots, D. R., P. A. Shaw, et al. (2010). "Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems." American journal of respiratory and critical care medicine 182(7): 970-976.
  23. Rahideh, S., P. Farnia, et al. (2014). "Isolation and identification of rapidly growing Mycobacteria from water and soil by PCR-RFLP method in Robat Karim." Journal of Health 4(4): 321-329.
  24. Set, R. and J. Shastri (2011). "Laboratory aspects of clinically significant rapidly growing mycobacteria." Indian journal of medical microbiology 29(4): 343.
  25. Shen, G.-H., B.-D. Wu, et al. (2007). "In vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan." Antimicrobial agents and chemotherapy 51(5): 1849-1851.
  26. Shenai, S., C. Rodrigues, et al. (2010). "Time to identify and define non-tuberculous mycobacteria in a tuberculosis-endemic region." The international journal of tuberculosis and lung disease 14(8): 1001-1008.
  27. Singh, A. K., A. K. Maurya, et al. (2013). "Role of genotype? mycobacterium common mycobacteria/additional species assay for rapid differentiation between Mycobacterium tuberculosis complex and different species of non-tuberculous mycobacteria." Journal of laboratory physicians 5(2): 83.
  28. Sriram, R. and P. Sarangan (2017). "Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated from cases of surgical site infections by microbroth dilution method at a Tertiary Care Center." Journal of Marine Medical Society 19(1): 6.
  29. , N. C. f. C. L. (2004). "Performance standards for antimicrobial susceptibility testing; 11th informational supplement. M100-S11." Wayne, PA: National Committee for Clinical Laboratory Standards.
  30. Stout, J. E., L. B. Gadkowski, et al. (2011). "Pedicure-associated rapidly growing mycobacterial infection: an endemic disease." Clinical Infectious Diseases 53(8): 787-792.
  31. Tang, S. S., D. C. Lye, et al. (2015). "Rapidly growing mycobacteria in Singapore, 2006?2011." Clinical Microbiology and Infection 21(3): 236-241.
  32. Thomson, R. M. (2010). "Changing epidemiology of pulmonary nontuberculous mycobacteria infections." Emerging infectious diseases 16(10): 1576.
  33. van Ingen, J., M. J. Boeree, et al. (2012). "Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria." Drug Resistance Updates 15(3): 149-161.
  34. Wallace, R., G. Bedsole, et al. (1990). "Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy." Antimicrobial agents and chemotherapy 34(1): 65-70.
  35. Wallace, R. J., B. A. Brown-Elliott, et al. (2002). "Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria." Antimicrobial agents and chemotherapy 46(10): 3164-3167.
  36. Welch, D. F. and M. T. Kelly (1979). "Antimicrobial susceptibility testing of Mycobacterium fortuitum complex." Antimicrobial agents and chemotherapy 15(6): 754-757.
  37. Winthrop, K. L., E. McNelley, et al. (2010). "Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease." American journal of respiratory and critical care medicine 182(7): 977-982.
  38. Yang, S.-C., P.-R. Hsueh, et al. (2003). "High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan." Antimicrobial agents and chemotherapy 47(6): 1958-1962.
  39. Yano, Y., S. Kitada, et al. (2013). "Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan." Respiration 85(4): 305-311.

How to Cite This Article

Jyoti Umrao, Dharamveer Singh, Amreen Zia, Swati Saxena, Surendra Sarsaiya and Tapan N. Dhole. (2018); ANTIMICROBIAL SUSCEPTIBILITY OF RAPID GROWING MYCOBACTERIA INFECTED PATIENTS WITH NTM AT TERTIARY CARE CENTER., Int. J. of Adv. Res., 6 (07), 1108-1113, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/7464

Corresponding Author

Dr.Tapan N. Dhole
Professor & Head Department of Microbiology Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.